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Abstract
Background: To reduce treatment variability and facilitate comparative effectiveness studies, the Childhood Arthritis
and Rheumatology Research Alliance (CARRA) published consensus treatment plans (CTPs) including one for juvenile
proliferative lupus nephritis (LN). Induction immunosuppression CTPs outline treatment with either monthly intravenous (IV)
cyclophosphamide (CYC) or mycophenolate mofetil (MMF) in conjunction with one of three corticosteroid (steroid) CTPs:
primarily oral, primarily IV or mixed oral/IV. The acceptability and in-practice use of these CTPs are unknown. Therefore, the
primary aims of the pilot study were to demonstrate feasibility of adhering to the LN CTPs and delineate
barriers to implementation in clinical care in the US. Further, we aimed to explore the safety and effectiveness of the
treatments for induction therapy.
Methods: Forty-one patients were enrolled from 10 CARRA sites. Patients had new-onset biopsy proven ISN/RPS class
III or IV proliferative LN, were starting induction therapy with MMF or IV CYC and high-dose steroids and were followed
for up to 24 months. Routine clinical data were collected at each visit. Provider reasons for CTP selection were assessed
at baseline. Adherence to the CTPs was evaluated by provider survey and medication logs. Complete and partial renal
responses were reported at 6 months.
Results: The majority of patients were female (83%) with a mean age of 14.7 years, SD 2.8. CYC was used more
commonly than MMF for patients with ISN/RPS class IV LN (vs. class III), those who had hematuria, and those with
adherence concerns. Overall adherence to the immunosuppression induction CTPs was acceptable with a majority of
patients receiving the target MMF (86%) or CYC (63%) dose. However, adherence to the steroid CTPs was poor (37%)
with large variability in dosing. Renal response endpoints were exploratory and did not show a significant difference
between CYC and MMF.
(Continued on next page)
* Correspondence: jennifer.cooper@childrenscolorado.org
1University of California, San Francisco, 550 16th Street, 5th Floor, San
Francisco, CA 94158, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cooper et al. Pediatric Rheumatology           (2018) 16:65 
https://doi.org/10.1186/s12969-018-0279-0
(Continued from previous page)
Conclusions: Overall, the immunosuppression CTPs were followed as intended in the majority of patients however,
adherence to the steroid CTPs was poor indicating revision is necessary. In addition, our pilot study revealed several
sources of treatment selection bias that will need to be addressed in for future comparative effectiveness research.
Keywords: Juvenile systemic lupus erythematosus, Lupus nephritis, Cyclophosphamide, Mycophenolate, Corticosteroids,
Consensus
Background
Systemic lupus erythematous (SLE) is a chronic and complex
autoimmune disease which causes systemic inflammation
and may involve any part of the body. Individuals diagnosed
in childhood or adolescence have more aggressive disease
compared to adults, with lupus nephritis (LN) occurring in
up to 80% of children [1]. The diagnosis of LN is established
by kidney biopsy and classified according to the 2004 Inter-
national Society for Nephrology/Renal Pathology Society
(ISN/RPS) criteria [2]. Proliferative lesions are classified as
class III if the lesion is focal or class IV if the lesion is diffuse,
involving over half the sampled glomeruli. Treatment usually
involves six months of aggressive induction immunosuppres-
sion to induce renal remission, followed by years of mainten-
ance immunosuppression aimed at preventing disease flares.
Progression to end-stage renal disease may occur despite
therapy with class IV LN patients at the greatest risk, esti-
mated at 44% over 15 years [3].
Data demonstrating optimal therapy for proliferative LN
in children and adolescents are lacking. Thus, there is sig-
nificant variability in the treatment of children and adoles-
cents with LN as providers rely upon extrapolation from
adult SLE studies, pediatric renal transplant literature, lim-
ited retrospective studies, and anecdotal experience to
guide medical decision-making [4]. In an effort to reduce
treatment variability and facilitate comparative effective-
ness studies in pediatric rheumatic diseases, Childhood
Arthritis and Rheumatology Research Alliance (CARRA)
developed Consensus Treatment Plans (CTPs) for several
pediatric diseases, including one for proliferative LN [4].
However, there is little information about the acceptability
and in-practice use of these CTPs.
Therefore, the primary aim of the pilot study was to
demonstrate feasibility of the LN CTPs in terms of ad-
herence to the treatment regimens and to delineate bar-
riers to implementation (reasons for not following the
CTPs) in clinical care in the United States. Further, we
aimed to explore the safety and effectiveness of the treat-
ments rendered upon completion of induction therapy.
Methods
Consensus treatment plans of LN
Details about these plans have been previously published
[4]. In brief, for induction therapy of proliferative LN,
CARRA CTPs recommend either intravenous (IV)
cyclophosphamide (CYC) 500–1000 mg/m2 (max
1500 mg) every 4 weeks × 6 months (6–7 doses) or myco-
phenolate mofetil (MMF) 600 mg/m2/dose BID (ma×
3000 mg/day) in addition to one of three high-dose cortico-
steroid (steroid) CTPs. Steroid CTP options include pri-
marily oral, primarily IV, or mixed oral/IV regimens.
High-dose pulse IV methylprednisolone 30 mg/kg (max
1000 mg/dose) × 3 doses is recommended at the start of
therapy in the primarily IV and mixed oral/IV steroid CTPs
and optional in the primarily oral steroid CTP. Tapering
schedules for prednisone or prednisolone are outlined for
each steroid regimen. Use of mesna, anti-emetics, gonado-
tropin releasing hormone agonists, and antimicrobials for
Pneumocystis jiroveci prophylaxis are at the provider’s dis-
cretion. Maintenance immunosuppression CTP options in-
clude MMF, azathioprine (AZA), or quarterly IV CYC in
addition to low-dose prednisone or prednisolone with a
goal to taper to ≤10 mg/day by 12 months and to ≤5 mg/
day by 24 months from the start of induction therapy.
Study design and patient population
A multicenter prospective observational cohort study
was conducted from May 2012 through October 2015.
Patients at participating sites were enrolled in the
CARRA registry and treated per the induction CTPs at
the discretion of the pediatric rheumatology provider.
Patients with complete or partial renal response at the
6-month visit were treated according to one of the three
maintenance CTPs. Main study entry criteria included
new diagnosis of biopsy-proven active proliferative LN
(ISN-RPS class III or IV) with or without concurrent
class V disease, fulfillment of ≥4 of 11 American College
of Rheumatology revised classification criteria for SLE or
presence of 3 criteria provided one is histological evi-
dence of LN [5], age at diagnosis with SLE ≤ 16 years,
and age at study enrollment ≤20 years. Exclusion criteria
were: severe infection, pregnancy or lactation, presence
of another chronic or genetic disease or organ involve-
ment that significantly influenced treatment of LN, and
treatment with MMF or CYC not indicated per provider.
Data collection
Study visits occurred at baseline and 3, 6, 9, 12, 18, and
24 months from the start of induction therapy.
Standard-of-care clinical and laboratory data were captured
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at each visit. Data was collected using standardized case re-
port forms through the InForm electronic data capture sys-
tem managed by the Duke Clinical Research Institute.
Patients or guardians were consented for data collection
through the Legacy CARRA registry. The Legacy CARRA
registry general protocol and consent was approved by
Duke University institutional review board (IRB) and all
participating site IRBs. Because the CTP study is not inter-
ventional and patients receive standard-of-care treatment at
the discretion of their provider, only consent for data collec-
tion as a participant in the CARRA registry was required.
Reasons for CTP selection
The provider’s reasons for CTP selection were assessed
using standardized responses (Table 1) with the ability
to select multiple reasons. Reasons for induction im-
munosuppression and steroid CTP selection were
assessed separately at baseline. Reasons for maintenance
immunosuppression CTP selection were assessed in re-
sponders at the 6-month visit.
Feasibility of LN CTPs
Adherence to induction immunosuppression and steroid
CTP regimens was assessed by medication log and
provider-report. Medications used during the study period
were recorded at every visit. Overall adherence to the in-
duction CTPs was evaluated by providers at the 3- and
6-month visits by asking whether the CTP had been
followed as intended. Reasons for not following a CTP
were assessed by multiple choice with ability to select
multiple reasons: patient non-adherence, patient-reported
intolerance, physician drug adjustment due to intolerance,
adverse event, disease flare, lack of response, laboratory
abnormality, pregnancy, and other.
Renal response
Renal response was assessed by providers at the
6-month visit. Responder criteria were established as
part of the previously published CARRA LN CTP and
adapted from the 2006 ACR response criteria for
proliferative and membranous renal disease in SLE clin-
ical trials [4, 6]. Complete renal response (CR) was de-
fined as normalization of estimated glomerular filtration
rate (GFR), inactive urine sediment (< 5 WBC/hpf, < 5
RBC/hpf, and no cellular casts) and spot urine
protein-to-creatinine ratio (UPCR) < 0.2 mg/mg. Partial
renal response (PR) was defined as at least 50% improve-
ment in two core renal parameters (GFR, urinary sedi-
ment, proteinuria), maximum UPCR of < 1.0 mg/mg,
and no clinically relevant worsening of the remaining
renal core parameters. Laboratory measures of renal
function were collected at every visit. GFR was estimated
using the modified Schwartz formula [7].
Disease activity
The Systemic Lupus Erythematosus Disease Activity
Index 2000 (SLEDAI-2 K) score was reported at baseline
and at each follow-up visit [8]. Providers assessed
whether the patient had experienced a disease flare since
the previous visit and whether the flare was renal or
non-renal. Specific flare criteria were not provided.
Safety
Adverse Events (AEs) were graded using the Common
Terminology Criteria for Adverse Events (CTCAE v4.0)
[9]. AEs of grade two and higher and serious adverse
events were recorded at each study visit. Serious AEs
were defined as death, life-threatening, hospitalization,
disability or permanent damage, congenital anomaly or
birth defect, or event that does not fit the defined out-
comes but may require intervention to prevent one of
the defined outcomes.
Statistical analyses
This was not a randomized study and comparisons of
baseline characteristics between CTP groups were per-
formed using Chi-square test, Fisher’s exact test, and Wil-
coxon rank sum tests to evaluate for possible biases
impacting CTP selection. To quantify deviation from the
oral steroid tapers during induction therapy, the difference
Table 1 Standardized responses used to assess reasons for consensus treatment plan (CTP) selection
Induction and maintenance immunosuppression CTPs Steroid CTPs
This is what I or my group always does This is what I or my group always does
This treatment works best I think this steroid regimen works best
This treatment is safer I think this steroid regimen is safer
This treatment is better tolerated I am concerned about my patient’s adherence with oral meds
I am concerned about my patient’s adherence with oral meds My patient prefers oral meds
This is the only option covered by my patient’s insurance Other (free text)
My patient prefers this method of medication administration
My patient is very concerned about side effects
Other (free text)
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between the expected dose recommended per the chosen
CTP and the reported daily dose was calculated for each
patient. An average percent daily difference for each week
of induction therapy was generated. Deviations from the
IV pulse component of the primarily IV and mixed steroid
CTPs were calculated similarly by taking the difference
between the expected (per CTP) and recorded number of
pulses in the medication log.
Exploratory analyses on clinical outcomes were per-
formed using multivariate logistic regression and mixed
effect models for repeated measures. The impact of induc-
tion immunosuppression treatment (CTP) on the renal re-
sponse at the 6-month visit was evaluated by multivariate
logistic regression analyses with adjustment of baseline
characteristics including age (years), proteinuria (mg/dL),
class of proliferative LN (III, IV), steroid CTP regimen
(primarily IV, mixed IV/oral, primarily oral). Colinearity of
continuous covariates were examined. Differences in lon-
gitudinal outcomes of GFR, proteinuria, and SLEDAI-2 K
between induction immunosuppression CTPs were
assessed using mixed models with repeated measures with
adjustment for baseline characteristics including age, gen-
der, time of scheduled visits, steroid CTP regimen, and
baseline values of these outcomes. Study treatment (CTP)
was considered a fixed effect and subjects were considered
random effects. Missing data points were considered miss-
ing at random. Multiple variance structures were explored
such as unstructured and spatial power. If convergence
was reached with multiple covariance structures, standard
goodness-of-fit measures were used to select the model
with the best fit. Statistical analyses were conducted using
STATA® 14.0 (StataCorp LLC) and SAS® 9.3 (SAS Institute
Inc.). All tests are two-sided. P-values were not adjusted
for multiple comparisons. Tests with p-values of < 0.05
were considered statistically significant.
Results
Patients
Eighty-five patients were screened with 41 patients ul-
timately enrolled at 10 CARRA sites. The most common
reasons for not participating were failure to meet inclu-
sion criteria (66%) and provider decision not to use a
CTP to guide treatment (20%). Baseline demographic
and clinical characteristics are shown in Table 2. Signifi-
cantly more patients in the CYC group had class IV LN
(79% vs. 35%, p = 0.005) and hematuria (96% vs. 47%,
p = 0.001) compared to the MMF group.
Study retention and visit timeliness
All patients completed at least 6 months of follow-up.
Retention declined over time with 35 (85%) and 18
(44%) patients completing the 12- and 24-month visits
respectively. Overall, 60% of visits occurred within four
weeks before or after the target visit date.
Induction CTP selection
CYC was selected for 24 (59%) patients and MMF for 17
(41%) patients (Fig. 1). Most sites used both regimens
(Fig. 2). The most common reasons for selecting CYC
were “This is what I or my group always does” (54%) and
“I think this treatment works best” (54%). Concern for pa-
tient non-adherence was the rationale for initiating CYC
for 8 patients. The most common reason for MMF selec-
tion was “This is what I or my group always does” (41%).
Of the three steroid CTPs, the mixed regimen was the
most commonly used (n = 17, 41%), followed by primarily
IV (n = 15, 37%), and primarily oral (n = 22%). Several sites
used only one regimen (Fig. 2). The most common reasons
for CTP selection were: “I always select this regimen” (47%)
and “This steroid regimen works best” (47%) for the mixed
group, “This steroid regimen works best” (80%) for the pri-
marily IV group, and “My patient prefers oral medications”
(33%) for the primarily oral group. IV-based steroid CTPs
(primarily IV and mixed) were more frequently used in
conjunction with CYC (p = 0.002).
Adherence to induction immunosuppression CTPs
Per medication logs, adherence to the immunosuppres-
sion CTPs was acceptable. In the MMF group, 84% and
86% of patients were at the target dose of ≥600 mg/m2
BID by the 3- and 6-month visits respectively, In the
CYC group, 63% received the expected number of 6 or 7
infusions; the median number of infusions was 6 (IQR
5–6). The median cumulative CYC dose was 6290 mg
(IQR 5040-8700). The median number of infusions was
6 (IQR 5–6) with a median monthly dose of 1100 mg/
m2 (IQR 849–1256).
Providers reported the immunosuppression CTPs were
followed as intended in 76% of patients at the 3-month
visit and 64% at the 6-month visit. The most common
reason for not following a CTP as intended was patient
non-adherence (17%). Although many providers re-
ported not following a CTP, the vast majority (95%) of
patients stayed on the initially selected treatment during
the first 6 months (Fig. 3). Two patients switched ther-
apy; one switched to MMF after the first CYC infusion
due to an allergic reaction and another switched to CYC
from MMF due to patient non-adherence. Two patients
were treated with additional immunosuppression during
the induction period. Concurrent medications are de-
scribed in Additional file 1.
Adherence to induction steroid CTPs
Oral steroid and IV pulse exposure through week 24 was
highly variable, indicating poor adherence to the steroid
CTPs (Table 3). For the primarily IV and mixed groups,
there was a tendency to prescribe fewer IV pulses than
outlined in the CTPs however, a substantial number of
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Table 2 Baseline characteristics overall and by induction immunosuppression CTP
All
n = 41
CYC
n = 24
MMF
n = 17
p-value
Demographics
Age at enrollment in years, mean (SD) 14.7 (2.8) 15.2 (2.9) 14 (2.6) 0.146
Age at SLE diagnosis in years, mean (SD) 13.8 (2.8) 13.8 (2.9) 13.7 (2.7) 0.832
SLE duration in weeks, median (IQR) 6 (1–73) 14 (3, 120) 5 (1, 10) 0.130
Female, n (%) 34 (83) 18 (75) 16 (94) 0.109
Race, n (%) 0.889
White 16 (39) 10 (42) 6 (35)
Black or African American 11 (27) 6 (25) 5 (29)
Asian or Pacific Islander 6 (15) 4 (17) 2 (12)
Other 8 (19) 4 (17) 4 (24)
Hispanic ethnicity, n (%) 11 (27) 6 (25) 5 (29) 0.753
Parental Income in US $/year, n/total (%) 0.798
< 25,000 6/26 (23) 4/15 (27) 2/11 (18)
25–49,999 8/26 (31) 3/15 (20) 5/11 (45)
50–74,999 2/26 (8) 1/15 (7) 1/11 (9)
75–99,999 6/26 (23) 4/15 (27) 2/11 (18)
100–150,000 2/26 (8) 2/15 (13) 0/11
> 150,000 2/26 (8) 1/15 (7) 1/11 (9)
Insured, n (%) 36 (88) 20 (83) 16 (94) 0.382
Clinical and laboratory characteristics
Lupus nephritis class, n (%) 0.005
ISN-RPS Class III, n (%) 16 (39) 5 (21) 11 (65)
ISN-RPS Class IV, n (%) 25 (61) 19 (79) 6 (35)
Concurrent ISN-RPS Class V LN, n (%) 14 (34) 6 (25) 8 (47) 0.142
GFR in ml/min/1.73 m2, median (IQR)a 94 (70–107) 93 (79–107) 95 (67–123) 0.864
Proteinuria in mg pr/mg cr, median (IQR)b 1.9 (1.1–4.7) 1.9 (1.3–4.6) 1.8 (0.8–4.7) 0.554
Hematuria present, n/total (%) 29/40 (73) 22/23 (96) 7/15 (47) 0.001
Hypertension, n/total (%)c 23/37 (62) 13/20 (65) 10/17 (59) 0.699
ESR in mm/hr., mean (SD) 50 (33) 44 (27) 60 (41) 0.304
Complement factor 3, median (IQR) 51 (39–75) 51 (39–71) 55 (31–98) 0.685
Complement factor 4, median (IQR) 6 (4–8) 6 (3–8) 6 (4–14) 0.578
Elevated dsDNA, n/total (%) 32/36 (89) 20/22 (91) 12/14 (86) 0.629
Antiphospholipid antibody present, n/total (%) 24/40 (60) 14/24 (58) 10/16 (63) 0.792
SLEDAI-2 K, median (IQR) 12 (8–20) 16 (10–20) 12 (6–22) 0.458
PGA, scale 0–10, median (IQR) 5 (3–6) 5 (3–6) 6 (2–6) 0.707
SLICC Damage Index, n/total (%) 0.677
Total Score 0 30/37 (81) 17/22 (77) 13/15 (87)
Total Score 1 7/37 (19) 5/22 (23) 2/15 (13)
Abbreviations: CTP consensus treatment plan, dsDNA double stranded DNA antibody, CR creatinine, GFR glomerular filtration rate, IQR interquartile range, ISN-RPS
International Society of Nephrology-Renal Pathology Society, IQR interquartile range, PGA Physician’s global disease activity, PR protein, SD standard deviation,
SLEDAI-2 K systemic lupus erythematosus disease activity index-2000, SLICC systemic lupus international collaborating clinics
aGFR estimated using modified Schwartz equation
bProteinuria assessed by spot urine protein to creatinine ratio
cHypertension defined as systolic or diastolic blood pressure ≥ 90th percentile, [21]
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patients (n = 22) had incomplete IV records and were
excluded from the IV analysis.
Providers reported adhering to the steroid CTPs in
68% of patients at 3 months and just 37% of patients at
6 months. Reasons for not following a steroid CTP were
similar across the regimens; the most common reasons
were patient non-adherence (22%) and other (17%). Re-
view of free-text responses revealed a theme of tapering
steroids more quickly than recommended.
Maintenance CTP selection and steroid use
Patients with CR or PR at the month 6 transitioned to a
maintenance CTP (n = 30). Twenty-eight patients (93%)
were treated with MMF, two (7%) with quarterly CYC,
and none with AZA. The most common reasons for
selecting MMF were “This is what I or my group always
does” (54%) and “I think this treatment works best” (54%).
The median prednisone or prednisolone dose at 24 weeks
for responders was 12 mg/day (IQR 10–20) or 0.2 mg/kg
(IQR 0.2–0.3). Of patients with complete tapering data at
12 months, 74% were in alignment with the CTP tapering
goal of ≤10 mg/day (median 7.7 mg/day or 0.2 mg/kg/day,
IQR 0.1–0.2). By 24 months, 78% were on a dose of ≤5 mg/
day (median 3.4 mg/day or 0.1 mg/kg/day, IQR 0–0.1).
Complete/partial renal response
Providers reported similar CR response rates for induc-
tion immunosuppression groups at 6 months; 46% of
patients in the CYC group and 47% in the MMF group.
Overall response (CR or PR) was reported in 83% (20/
24) of patients in the CYC group vs. 59% (10/17) in the
MMF group (p = 0.08). There was no significant differ-
ence between CYC and MMF and renal response (CR or
PR) in multivariate logistic regression after controlling
for age, gender, proliferative LN class, and steroid CTP.
Provider assessment of renal response (CR, PR) was
confirmed by laboratory values in 24 of 41 (59%) patients.
However, we were unable to corroborate the provider’s as-
sessment in 17 patients due to: missing laboratory data
(n = 9) and inconsistency between the laboratory values
and the reported response (n = 8). To conservatively esti-
mate the proportion of patients achieving renal response
(CR or PR) at the 6-month visit using only the reported la-
boratory data, we counted the nine patients with missing
data as non-responders, resulting in a CR rate just above
40% for both CYC (10/24, 42%) and MMF (7/17, 41%)
groups. The total proportion of responders (CR or PR) in
the CYC group was 63% (15/24) and 53% (9/17) in the
MMF group, p = 0.54. Courses of non-responders are
summarized in Additional file 2.
Longitudinal outcomes: Proteinuria, GFR, SLEDAI-2 K
Median GFR, proteinuria, and SLEDAI-2 K scores over
the course of the study are shown in Fig. 4. Exploratory
analyses evaluating the effect of induction immunosup-
pression CTP (CYC vs. MMF) on outcomes of
Screened
n = 85
Enrolled 
n = 41
CYC  
n = 24
Primarily IV 
n = 9
Mixed IV/oral
n = 14
Primarily oral
n = 1
MMF 
n = 17
Primarily IV
n = 6
Mixed IV/oral
n = 3
Primarily oral
n =  8
Immunosuppression CTP 
         Corticosteroid CTP 
Fig. 1 Enrollment and induction CTP selection. Abbreviations: CTP = consensus treatment plan, CYC = cyclophosphamide, IV = intravenous, MMF
=mycophenolate mofetil, IV = intravenous
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proteinuria, GFR, and SLEDAI-2 K over the study period
were conducted using mixed effects models. No signifi-
cant differences were found between CYC and MMF
groups and GFR, proteinuria, or SLEDAI-2 K over time.
Disease flares
Of the 30 patients with a CR or PR at month 6, four pa-
tients experienced disease flare (2 renal flares) by month
24; all four patients were on MMF at the time of flare.
Adverse events
AEs are summarized in Table 4. Two serious adverse
events were reported during the 6-month induction
period; one patient was hospitalized for depression and
suicidal ideation and one patient developed an oppor-
tunistic infection. Study is available in Additional file 3.
Discussion
Our pilot study illustrates the feasibility of adhering to
the CARRA LN CTPs in clinical practice and collecting
observational longitudinal data across ten US pediatric
rheumatology centers. Most importantly, this study
elucidates the need for revision of the steroid CTPs to
reduce treatment variability and support future com-
parative effectiveness research as adherence to the ster-
oid CTPs was poor (37% at 6 months) with large
variability in dosing. The original CTP development
process utilized case-based surveys to assess current
practice of the CARRA membership and it is possible
that the theoretical cases used to develop the CTPs did
not allow for assessment of real-life nuance, treatment
practices have changed, or the providers in this pilot
study were not representative of those surveyed during
the initial consensus process. Thus, as the current ster-
oid CTPs do not seem to be representative of common
use we recommend revision to include a faster tapering
option for patients with early response to therapy or for
those with dose-limiting steroid toxicity or intolerance.
We characterized physician decision-making and identi-
fied treatment biases that will be important to consider
when designing future comparative effectiveness studies.
Overall, the most common reason for selecting a particu-
lar CTP was “This is what I or my group always does” sug-
gesting that although the aim was develop CTP options
Fig. 2 Induction CTP selection by study site. Abbreviations: CTP = consensus treatment plan, CYC = cyclophosphamide, MMF =mycophenolate mofetil
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that were considered equivalent in effectiveness and
would be equally acceptable as standard-of-care, providers
may still have strong treatment preferences. Perhaps not
surprisingly, there was a tendency to treat patients with
class IV LN (vs. class III), hematuria, and compliance con-
cerns with CYC. In addition, we observed increased use of
the IV-based steroid CTPs (primarily IV and mixed) in the
CYC group. While this is not surprising from a practical
standpoint because it is more convenient for patients
already receiving one IV medication to receive another, it
may also reflect a tendency to treat patients with more se-
vere disease and/or poor compliance with IV medications.
Strategies to reduce the effects of confounding by indica-
tion such as cluster (site) randomization or statistical ad-
justment with propensity matching could be implemented
in future CTP studies.
Another potential barrier to CTP implementation
highlighted in this study will be developing a process to ef-
ficiently update CTPs as practice patterns evolve. Al-
though 90% of pediatric rheumatologists surveyed during
the CTP development process endorsed using CYC
first-line for induction treatment of proliferative LN, the
CYC CTP was used in 63% of patients [4]. In addition, the
vast majority (93%) of patients received MMF for
Fig. 3 Pattern of CYC and MMF use and duration of follow-up. Abbreviations: CYC = cyclophosphamide, MMF =mycophenolate mofetil
Table 3 Induction corticosteroid exposure through week 24 by CTP*
Steroid Primarily IV
N = 15
Mixed Oral/IV
N = 17
Primarily Oral
N = 9
Oral prednisone or prednisolone
n patients with complete med loga 14 14 9
Total gm 5.8 (4–8.4) 8.4 (6.2–9.2) 16.1 (7.7–17.7)
Total mg/kg 119 (72–142) 144 (94–160) 285 (114, 313)
Difference from expected, mgb − 108 (− 685, + 65) + 367 (− 692, + 1440) − 338 (− 2650, + 1620)
IV methylprednisolone pulses
n patient with complete med logsa 9 9 5
Total number of pulse doses 12 (6–14) 5 (3–8) 1 (0, 3)
Difference from expected, number of pulsesb − 1 (− 7, 0) −5 (− 5, 0) 0 (0, 0)c
*All values presented as median (interquartile range), Abbreviations: CTP = Consensus treatment plan, IV = intravenous
aPatients with incomplete steroid records were excluded from analysis
bDifference from expected per CTP. A positive value (+) indicates more steroid was given than recommended per the CTP. A negative value (−) indicates less
steroid was given per the CTP
cIV pulses optional in the primarily oral CTP
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maintenance therapy. Taken together, these results likely
reflect increased use of MMF by pediatric rheumatologists
since development of the LN CTPs. In addition, the lack
of AZA use for maintenance therapy is surprising given
the comparable effectiveness to MMF demonstrated in
adults [10–12], lower cost, and option for once daily dos-
ing. During the LN CTP development process, the
low-dose “Euro-lupus” IV CYC regimen was not included
as an option because of the lack of dosing guidelines for
children and because the CTPs are designed to reflect
current practice and the Euro-lupus regimen was not
commonly used by CARRA pediatric rheumatologists. In
recent years, several U.S. pediatric rheumatology centers
have begun using the Euro-lupus regimen in adolescents
Fig. 4 Estimated GFR, proteinuria, and SLEDAI over the study period by induction immunosuppression CTP. Abbreviations: CTP = consensus treatment
plan, GFR = estimated glomerular filtration rate, SLEDAI = systemic lupus erythematosus disease activity index-2 K, StdErr = standard error
Table 4 Adverse Events
Patient AE Medications at time of AE AE Grade SAE Timing
1 Depression with suicidal ideation CYC, Mixed CS 3 Yes Induction
2 Opportunistic infection MMF, Mixed CS 2 Yes Induction
3 Infusion reaction CYC, Primarily IV CS 3 No Induction
4 Steroid intolerance MMF, Mixed CS 2 No Induction
5 Hypertension MMF, Mixed CS 3 Yes Maintenance
6 Acute appendicitis MMF 3 Yes Maintenance
7 Chest pain Mycophenolic acid, low-dose prednisone* 2 No Maintenance
8 Gastroenteritis MMF. low-dose prednisone* 2 No Maintenance
9 Pyelonephritis MMF, low-dose prednisone* 2 Yes Maintenance
Abbreviations: AE adverse event, CS corticosteroid, CYC cyclophosphamide, MMF mycophenolate mofetil, SAE Serious adverse event
*Low-dose prednisone = 10 mg/day or less
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in light of data in adults demonstrating comparable
long-term renal outcomes and lower risk of ovarian tox-
icity compared to conventional dosing [13, 14].
As the main objectives of this pilot study were to as-
sess feasibility of adhering to the CTPs in clinical prac-
tice, the study was not powered to assess differences in
clinical response between treatment groups. In an ex-
ploratory analysis estimating renal response using la-
boratory data and with patients with missing data as
non-responders, both CYC and MMF groups had a CR
rate just above 40% at the 6-month visit. Renal response
criteria for LN are far from standardized however, when
similar CR criteria (proteinuria < 500 mg/24 h, no wors-
ening of GFR at 6 months) were applied to raw data sets
from three large adult LN trials (Aspreva Lupus Man-
agement Study, Abatacept and Cyclophosphamide Com-
bination Efficacy and Safety Study, and Euro-lupus
Nephritis Trial), response rates for MMF, high-dose IV
CYC, and low-dose IV CYC all groups showed CR rates
of approximately 20%, substantially lower than our study
[15–18]. Several factors that may contribute to this find-
ing. First, this study included only new-onset prolifera-
tive LN patients while most adult proliferative LN trials
do not exclude patients with prior LN flares and these
patients may be less likely to achieve a CR. Second,
many patients in the current study had their 6-month
visit assessment late, leading to more time on therapy
before outcome assessment, which could have favorably
affected the response rate.
Our pilot study has several limitations. We were un-
able to corroborate provider assessment of renal re-
sponse in many patients, most often due to missing
laboratory values but there were also instances where
the provider’s assessment did not match the reported la-
boratory data, raising concern regarding future use of
provider response ascertainment. The inconsistency may
indicate that the response criteria is difficult to apply in
clinical practice and highlights the challenge of using re-
search assessment tools designed for use in RCTs in the
pragmatic study setting. Importantly, since this study
was conducted, the CARRA registry has implemented
measures to reduce missing data and improve data qual-
ity. In addition to known biases, this study is subject to
bias from unmeasured confounders. Examples of poten-
tial unmeasured confounders in the current study are
renal histopathology disease activity and chronicity and
patient adherence. Baseline renal biopsy detail regarding
activity and chronicity was not systematically collected
but may have influenced provider decision-making re-
garding CTP selection. Poor medication adherence has
been associated with poor renal outcomes in adults [19,
20] and although provider concern for poor adherence
to oral medications was found to influence CTP selec-
tion, individual patient adherence data was not recorded
and is difficult to measure. Lastly, given the small sam-
ple size, results from this feasibility study should be
interpreted with caution.
Conclusions
In summary, our pilot study demonstrates that the gen-
eral approach of using the CARRA LN CTPs in clinical
practice for observational research is feasible, however
we identified several key issues to consider going for-
ward, particularly revision of the steroid CTPs, deter-
mination of renal response, and strategies to reduce
effects of confounding by indication.
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